{"fetched":"2026-10-01","feeds":[{"id":"fda-oce","name":"FDA Oncology Center of Excellence","homepage":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","kind":"regulator","sourceId":"fda-approvals","ok":true,"count":9},{"id":"nejm","name":"New England Journal of Medicine","homepage":"https://www.nejm.org/","url":"https://www.nejm.org/action/showFeed?type=etoc&feed=rss&jc=nejm","kind":"journal","sourceId":"nejm","onlyOncology":true,"ok":false,"count":3,"error":"unreachable or blocked; showing 3 items from 2026-09-24"},{"id":"lancet-oncology","name":"The Lancet Oncology","homepage":"https://www.thelancet.com/journals/lanonc/home","url":"https://www.thelancet.com/rssfeed/lanonc_current.xml","kind":"journal","sourceId":"lancet-oncology","ok":true,"count":40},{"id":"jco","name":"Journal of Clinical Oncology","homepage":"https://ascopubs.org/journal/jco","url":"https://ascopubs.org/action/showFeed?type=etoc&feed=rss&jc=jco","kind":"journal","sourceId":"jco","ok":true,"count":40},{"id":"nature-medicine","name":"Nature Medicine","homepage":"https://www.nature.com/nm/","url":"https://www.nature.com/nm.rss","kind":"journal","sourceId":"nature-medicine","onlyOncology":true,"ok":true,"count":4},{"id":"endpoints","name":"Endpoints News","homepage":"https://endpts.com/","url":"https://endpts.com/feed/","kind":"news","sourceId":"src-endpoints-news","onlyOncology":true,"ok":true,"count":3},{"id":"stat","name":"STAT","homepage":"https://www.statnews.com/","url":"https://www.statnews.com/feed/","kind":"news","sourceId":"src-stat-news","onlyOncology":true,"ok":true,"count":1}],"items":[{"feedId":"lancet-oncology","title":"[Editorial] Microplastics and cancer: a looming threat?","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00483-3/fulltext","date":"2026-10-01","refs":["lung-cancer","a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Looking at cancer burden in Africa through a new lens","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00381-5/fulltext","date":"2026-10-01","refs":["nct06936774","nct07257653","a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Blank spaces on the map: genomics for global cancer research","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00460-2/fulltext","date":"2026-10-01","refs":[]},{"feedId":"lancet-oncology","title":"[Comment] England's National Cancer Plan; ambition without accountability","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00458-4/fulltext","date":"2026-10-01","refs":[]},{"feedId":"lancet-oncology","title":"[Correspondence] Re-evaluating aglatimagene in localised prostate cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00356-6/fulltext","date":"2026-10-01","refs":["aglatimagene-besadenovec","aurora","prostate"]},{"feedId":"lancet-oncology","title":"[Correspondence] Re-evaluating aglatimagene in localised prostate cancer – Authors' reply","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00462-6/fulltext","date":"2026-10-01","refs":["prostate"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00344-X/fulltext","date":"2026-10-01","refs":["stage-iii-unresectable-nsclc","nsclc","sclc","lung-cancer","durvalumab","pacific","nct07221474"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00397-9/fulltext","date":"2026-10-01","refs":["durvalumab","pacific","nct07221474"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00402-X/fulltext","date":"2026-10-01","refs":["stage-iii-unresectable-nsclc","nsclc","sclc","lung-cancer","durvalumab","pacific","nct07221474","nct06745882"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00444-4/fulltext","date":"2026-10-01","refs":["durvalumab","pacific","nct07221474"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC – Authors' reply","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00475-4/fulltext","date":"2026-10-01","refs":["durvalumab","pacific"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 1043–56","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00484-5/fulltext","date":"2026-10-01","refs":["stage-iii-unresectable-nsclc","nsclc","sclc","lung-cancer","nct05035745","nct05281471","nct06463665","nct06590246"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 1077–93","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00472-9/fulltext","date":"2026-10-01","refs":["tace","hcc","tremelimumab","lenvatinib","nct04875585","durvalumab","emerald-3","emerald"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 1094–109","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00473-0/fulltext","date":"2026-10-01","refs":["egfr-mutant-nsclc","nsclc","sclc","nct07381309","ivonescimab","lung-cancer","nct05035745","nct06590246"]},{"feedId":"lancet-oncology","title":"[Perspectives] Cancer's new anxiety: not a death sentence, but delay","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00476-6/fulltext","date":"2026-10-01","refs":[]},{"feedId":"lancet-oncology","title":"[Perspectives] Against cancer, not against dying: Ernest Becker in the oncology clinic","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00477-8/fulltext","date":"2026-10-01","refs":["colorectal"]},{"feedId":"lancet-oncology","title":"[Perspectives] Differing approaches to cancer at the Edinburgh Fringe","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00478-X/fulltext","date":"2026-10-01","refs":["chordoma"]},{"feedId":"lancet-oncology","title":"[Articles] Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00307-4/fulltext","date":"2026-10-01","refs":["hpv-vaccine","anal","anchor"]},{"feedId":"lancet-oncology","title":"[Articles] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00297-4/fulltext","date":"2026-10-01","refs":["breast-cancer","nct06949111"]},{"feedId":"nature-medicine","title":"Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial","url":"https://www.nature.com/articles/s41591-026-04705-y","date":"2026-09-30","refs":["metastatic-pdac","pancreatic","nct07353645","nct07381309"]},{"feedId":"endpoints","title":"AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117","url":"https://endpoints.news/abbvies-eczema-drug-shows-benefit-in-phase-2-biomarin-lays-off-117/","date":"2026-09-30","refs":["nct07106762","abbvie"]},{"feedId":"endpoints","title":"Ned Sharpless joins Hatteras, as Andrew Witty returns to the VC firm as chairman","url":"https://endpoints.news/ned-sharpless-joins-hatteras-as-andrew-witty-returns-to-the-vc-firm-as-chairman/","date":"2026-09-30","refs":[]},{"feedId":"jco","title":"Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01114","date":"2026-09-29","refs":["sentinel-node","breast-cancer","nct07381309","nct05562297","nct07412613","nct05035745","nct06590246"]},{"feedId":"jco","title":"Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00735","date":"2026-09-29","refs":["brca"]},{"feedId":"nature-medicine","title":"A synthetic lethal drug for microsatellite instability cancers","url":"https://www.nature.com/articles/s41591-026-04693-z","date":"2026-09-29","refs":[]},{"feedId":"nature-medicine","title":"Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial","url":"https://www.nature.com/articles/s41591-026-04657-3","date":"2026-09-29","refs":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221"]},{"feedId":"endpoints","title":"Spark co-founder Steven Altschuler is back with an immune-resetting biotech","url":"https://endpoints.news/spark-co-founder-steven-altschuler-is-back-with-an-immune-resetting-biotech/","date":"2026-09-29","refs":["car-t","mcla-129","adienne"]},{"feedId":"stat","title":"STAT+: AstraZeneca invests $2 billion in Summit Therapeutics","url":"https://www.statnews.com/2026/09/29/biotech-news-astrazeneca-invests-2-billion-in-summit-therapeautics/?utm_campaign=rss","date":"2026-09-29","refs":["summit-therapeutics","ivonescimab","astrazeneca","mcla-129","nct07277842","pd1","vegf","ai-081"]},{"feedId":"nature-medicine","title":"Biography of an inherited lung cancer risk gene","url":"https://www.nature.com/articles/d41591-026-00048-w","date":"2026-09-28","refs":["lung-cancer"]},{"feedId":"lancet-oncology","title":"[Comment] Personalised medicine in oncology: inequality aversion in a fast-moving field","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00435-3/fulltext","date":"2026-09-25","refs":["cancer-of-unknown-primary","companion-diagnostic","a16z-bio-health","state-arc"]},{"feedId":"lancet-oncology","title":"[Comment] Ethical priorities in global cancer genomics and precision oncology","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00442-0/fulltext","date":"2026-09-25","refs":["a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Inequities in access to precision oncology: shared challenges, unified blueprint","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00448-1/fulltext","date":"2026-09-25","refs":["nct06936774","toshiba-energy-systems","a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Beyond the evidence: why multistakeholder cooperation will determine whether cancer genomics reaches patients","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00437-7/fulltext","date":"2026-09-25","refs":[]},{"feedId":"lancet-oncology","title":"[Comment] Ecological neglect: critical oversight in precision oncology governance","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00407-9/fulltext","date":"2026-09-25","refs":["nct05035745","nct06590246","a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Affordability in the era of precision oncology","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00436-5/fulltext","date":"2026-09-25","refs":["nct05281471","nct06463665","a16z-bio-health","gdf7"]},{"feedId":"lancet-oncology","title":"[Comment] Counting who was not tested: artificial intelligence extraction of genomic and treatment data from hospital records","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00449-3/fulltext","date":"2026-09-25","refs":["a16z-bio-health"]},{"feedId":"jco","title":"Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00401","date":"2026-09-25","refs":["multiple-myeloma","dexamethasone","lenalidomide","daratumumab","bortezomib","cepheus"]},{"feedId":"fda-oce","title":"FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component","date":"2026-09-24","refs":["rcc","lenvatinib","nct04875585","belzutifan","nct04924075","nct05035745","nct06590246","eisai"]},{"feedId":"jco","title":"First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02933","date":"2026-09-24","refs":["egf","retlirafusp-alfa","urethral-adenocarcinoma","lung-adenocarcinoma","nct07381309","gastric","gdf7","alfa"]},{"feedId":"fda-oce","title":"FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic","date":"2026-09-23","refs":["elevar-therapeutics","lirafugratinib","nct05035745","nct06590246","gdf7","fgfr2","beone"]},{"feedId":"jco","title":"Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00017","date":"2026-09-23","refs":["cholangiocarcinoma","biliary-tract-cancer","ascot-jcog1202","scot"]},{"feedId":"jco","title":"When Survival Separates","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00371","date":"2026-09-22","refs":[]},{"feedId":"jco","title":"Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02766","date":"2026-09-22","refs":["melanoma","braf"]},{"feedId":"jco","title":"Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02476","date":"2026-09-21","refs":["ductal-carcinoma-in-situ"]},{"feedId":"fda-oce","title":"FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or","date":"2026-09-18","refs":["breast-hr-positive","nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886"]},{"feedId":"jco","title":"Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02737","date":"2026-09-18","refs":["a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[News] 2026 World Conference on Lung Cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00480-8/fulltext","date":"2026-09-17","refs":["adc","sclc","nct06498479","lung-cancer","topotecan","nct05947851","b7h3","nct07728955"]},{"feedId":"lancet-oncology","title":"[News] Kenya agrees major cuts to cancer drug prices","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00481-X/fulltext","date":"2026-09-17","refs":["multiple-myeloma","burkitt-lymphoma","leukaemia","burkitt-leukaemia","non-hodgkin-lymphoma","nct07075328","pfizer"]},{"feedId":"lancet-oncology","title":"[News] Toxic dust around the World Trade Center","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00482-1/fulltext","date":"2026-09-17","refs":["a16z-bio-health"]},{"feedId":"jco","title":"Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA–Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01914","date":"2026-09-16","refs":["nct07095309","nct05954078","colorectal","nct06936774"]},{"feedId":"jco","title":"Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-01967","date":"2026-09-16","refs":[]},{"feedId":"jco","title":"Recent Population-Level Trends in Utilization of Outpatient Medical Oncology Services","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01156","date":"2026-09-15","refs":[]},{"feedId":"jco","title":"Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00285","date":"2026-09-15","refs":["childrens-oncology-group","ewing-sarcoma"]},{"feedId":"jco","title":"Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00785","date":"2026-09-15","refs":[]},{"feedId":"jco","title":"Bridging the Gap: Precision Oncology for Cancers of Unknown Primary","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01847","date":"2026-09-14","refs":[]},{"feedId":"jco","title":"P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR–Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00556","date":"2026-09-14","refs":["nsclc","nct06745882","nct07728955","nct06441344","egfr","nct07617805"]},{"feedId":"lancet-oncology","title":"[Articles] Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00305-0/fulltext","date":"2026-09-11","refs":["lung-cancer"]},{"feedId":"jco","title":"Acknowledgment of Reviewers 2026","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01815","date":"2026-09-11","refs":[]},{"feedId":"jco","title":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00602","date":"2026-09-11","refs":["egf","trastuzumab-emtansine","breast-cancer","trastuzumab","nct06891833","nct05035745","nct06590246","gdf7"]},{"feedId":"lancet-oncology","title":"[News] Increased tobacco production and cigarette imports in Africa","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00461-4/fulltext","date":"2026-09-10","refs":[]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small","date":"2026-09-09","refs":["nct05318573","sevabertinib","lung-cancer","nct05035745","lung-squamous-cell-carcinoma","nct06590246","nsclc","nct06745882"]},{"feedId":"jco","title":"Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00769","date":"2026-09-09","refs":["nct06976944","nct04153734","pembrolizumab","nct05224141","nct06949111","sarcoma"]},{"feedId":"jco","title":"LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00451","date":"2026-09-09","refs":["dlbcl","nct05487170","bcl10","bcl11b","non-hodgkin-lymphoma","nct07075328"]},{"feedId":"jco","title":"Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01423","date":"2026-09-09","refs":["egf","breast-cancer","nct05562297","nct07412613","gdf7"]},{"feedId":"jco","title":"Purple Blossoms","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00469","date":"2026-09-08","refs":[]},{"feedId":"lancet-oncology","title":"[Articles] Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00223-8/fulltext","date":"2026-09-07","refs":["ovarian","nct06976944","nct04153734","pembrolizumab","nct05224141","nct07381309","nct05035745","olaparib"]},{"feedId":"lancet-oncology","title":"[Articles] Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00286-X/fulltext","date":"2026-09-07","refs":["multiple-myeloma","nct06771609","cyclophosphamide","dexamethasone","lenalidomide","daratumumab","bortezomib","nct05222971"]},{"feedId":"lancet-oncology","title":"[Perspectives] Sir Chris Hoy's Tour de 4 charity cycle ride returns","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00330-X/fulltext","date":"2026-09-06","refs":["prostate"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative","date":"2026-09-04","refs":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","egf"]},{"feedId":"lancet-oncology","title":"[Comment] Exercise oncology: from trials and guidelines to routine clinical care","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00386-4/fulltext","date":"2026-09-04","refs":["exercise-oncology"]},{"feedId":"lancet-oncology","title":"[Articles] An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00304-9/fulltext","date":"2026-09-04","refs":["androgen-deprivation","prostate","exercise-oncology"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 181–90","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00405-5/fulltext","date":"2026-09-03","refs":[]},{"feedId":"jco","title":"Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02974","date":"2026-09-03","refs":["cancer-of-unknown-primary","nct07381309","nct05744687","nct05281471","nct06463665","nct07290088","cupisco"]},{"feedId":"jco","title":"Bridging the Gap: Mounting Evidence for Metastasis-Directed Therapy in Oligometastatic Disease","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01339","date":"2026-09-02","refs":[]},{"feedId":"nejm","title":"Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2504059?af=R&rss=currentIssue","date":"2026-09-02","refs":["nsclc","sclc","daraxonrasib"]},{"feedId":"nejm","title":"Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2602804?af=R&rss=currentIssue","date":"2026-09-02","refs":["azacitidine","venetoclax"]},{"feedId":"nejm","title":"Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML","url":"https://www.nejm.org/doi/full/10.1056/NEJMe2607967?af=R&rss=currentIssue","date":"2026-09-02","refs":["venetoclax"]},{"feedId":"jco","title":"Bridging the Gap: Clinical Integration of Thrombopoietin Receptor Agonists in GI Cancer–Associated Chemotherapy-Induced Thrombocytopenia","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01447","date":"2026-09-01","refs":["nct07381309"]},{"feedId":"jco","title":"Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02659","date":"2026-08-28","refs":["nct05318573","lung-cancer","durvalumab","nct03800134"]},{"feedId":"lancet-oncology","title":"[News] Delays in cancer referrals and care lead to harm and missed diagnoses in England","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00443-2/fulltext","date":"2026-08-27","refs":["a16z-bio-health"]},{"feedId":"jco","title":"Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00161","date":"2026-08-27","refs":["lls-therapy-acceleration-program","leukaemia"]},{"feedId":"jco","title":"Targeting ErbB-Family Receptors in Small Cell Lung Cancer: Clinical Activity and an Unresolved Mechanism","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01469","date":"2026-08-27","refs":["lung-cancer"]},{"feedId":"jco","title":"Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00355","date":"2026-08-27","refs":["nct07683403","nct07535632","nct06992258","colorectal","bevacizumab-glioma","bevacizumab","nct06791512","nct07007767"]},{"feedId":"fda-oce","title":"FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma","date":"2026-08-26","refs":["pancreatic","revolution-medicines","urethral-adenocarcinoma","lung-adenocarcinoma","daraxonrasib","beone"]},{"feedId":"fda-oce","title":"FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction","date":"2026-08-25","refs":["oesophageal-adenocarcinoma","jazz","beone","urethral-adenocarcinoma","lung-adenocarcinoma","tislelizumab","nct07381309","zanidatamab"]},{"feedId":"jco","title":"The Patient Who Could Not Die","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02505","date":"2026-08-25","refs":[]},{"feedId":"jco","title":"Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00640","date":"2026-08-25","refs":["recurrent-metastatic-nasopharyngeal-carcinoma","nasopharyngeal","pucotenlimab","platinum-etoposide"]},{"feedId":"jco","title":"Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02234","date":"2026-08-25","refs":["nct06949111"]},{"feedId":"jco","title":"Erratum: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-02036","date":"2026-08-24","refs":["childrens-oncology-group","doxorubicin","dexrazoxane"]},{"feedId":"jco","title":"Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-03080","date":"2026-08-24","refs":["rhabdomyosarcoma","fdg-pet"]},{"feedId":"lancet-oncology","title":"[News] Trump cuts childhood vaccine recommendations","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00433-X/fulltext","date":"2026-08-20","refs":[]},{"feedId":"lancet-oncology","title":"[News] Nigeria plans major expansion of radiotherapy capacity","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00434-1/fulltext","date":"2026-08-20","refs":["nct06949111"]},{"feedId":"jco","title":"Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02255","date":"2026-08-20","refs":["breast-her2-positive","breast-cancer","trastuzumab","nct06891833","pertuzumab","nct04514419","her2"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone","date":"2026-08-13","refs":["bms","multiple-myeloma","dexamethasone","daratumumab","iberdomide","proteasome"]},{"feedId":"jco","title":"Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-01846","date":"2026-08-12","refs":[]},{"feedId":"jco","title":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00852","date":"2026-08-11","refs":["advanced-melanoma","nct05562297","nct07412613","melanoma","nct05035745","nct05281471","nct06463665","nct06590246"]},{"feedId":"jco","title":"Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00428","date":"2026-08-07","refs":["nct06943872","nct05947851","nct05704049","nct01827605","lls-therapy-acceleration-program","leukaemia"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma","date":"2026-08-06","refs":["vusolimogene-oderparepvec","nct05663775","nivolumab","relatlimab-nivolumab","replimune","melanoma","nct05035745","nct06037655"]},{"feedId":"jco","title":"Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00260","date":"2026-08-06","refs":["childrens-oncology-group","doxorubicin","dexrazoxane"]},{"feedId":"jco","title":"Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01898","date":"2026-08-06","refs":["prostate-mcrpc","prostate"]}]}